Secukinumab demonstrates efficacy, safety and tolerability upon administration by 2 mL autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
Secukinumab demonstrates efficacy, safety and tolerability upon administration by 2 mL autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial
创建时间：
2021-05-28
